RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.comCanada Is Newest Market for Identafi™ 3000 Ultra, World's Leading Oral Cancer Detection Device – Houston's Trimira LLC Expands North American Distribution
With Grant of Canadian Medical Device Establishment LicenseHOUSTON, September 28, 2009 — Identafi™ 3000 ultra, the world's leading oral cancer detection device and the only one to feature the revolutionary "multispectral" optical fluorescence and reflectance technology, is now available in Canada.
Trimira VP, Marketing Jerry S. Trzeciak noted that Trimira™ LLC just received its Canadian Medical Device Establishment License, enabling sales of Identafi™ 3000 ultra to proceed in Canada, broadening the product's North American market penetration.
Identafi™ 3000 ultra will be sold through dealer/distributor networks in Canada."Actually, Identafi 3000 ultra's science pedigree is one part Canadian, because the prestigious British Columbia Cancer Research Centre in Vancouver, Canada, is one of the research centers responsible for developing Identafi's patented multispectral spectroscopy," Trzeciak said. "This technology also was developed in concert with The University of Texas M.D. Anderson Cancer Center and Rice University in Houston."
He noted that multispectral technology has been characterized as a quantum leap in the visualization of mucosal abnormalities, including oral cancer or premalignant dysplasia."Our goal is to broaden the global distribution of Identafi 3000 ultra," Trzeciak said. "Multispectral spectroscopy itself has no peer in its reliability, speed, and precision in detecting cancer and pre-cancer in the oral cavity. The technology," he added, "reflects 15 years and $30 million of research at three world-class cancer centers and the support of a highly dedicated cancer research philanthropist, T. Boone Pickens."
Identafi Developed Expressly for Intraoral Use
The small, cordless Identafi™ 3000 ultra was created exclusively for intraoral use. The optical device minimizes false positives/negatives and reveals abnormalities in oral tissue missed by the naked eye. The lightweight, dental-friendly design of Identafi™ 3000 ultra enables its bright light source to fit into the mouth, which means that the user can see the base of the tongue, where a large percentage of deadly tumors are found.
Identafi™ 3000 ultra
Identafi™ 3000 ultra is portable and ergonomically shaped for dentists, periodontists, oral surgeons, otolaryngologists, and primary-care physicians. The internationally award-winning handheld incorporates next-generation oral cancer-detection advances that are changing the screening and diagnostic landscape for dentists and doctors.
Identafi™ 3000 ultra is the only optical dental device on the market that illuminates with three wavelengths of brilliant white, violet, and green-amber light. Unlike other methods, it empowers doctors and dentists to pinpoint biochemical and morphological changes in cells. Its one-of-a-kind multispectral technology not only is effective in screening oral cancers but also in diagnosing cervical, skin, gastrointestinal, and bladder cancers.
About Trimira™ LLC
Trimira™ LLC is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Other Trimira sister subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit Trimira™ at: http://www.trimira.net
Animations
Identafi® Technology
Identafi® 3000 ultra Process
Screening Results
Training
